메뉴 건너뛰기




Volumn 62, Issue 3, 2004, Pages 254-272

Pharmacogenomics of the P53 tumor suppressor and its role in cancer chemoresistance

Author keywords

Chemoresistance; Chemosensitivity; Mutation; p53 tumor suppressor; Pharmacogenomics

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; IRINOTECAN; METHOTREXATE; PACLITAXEL; PIRARUBICIN; PROTEIN P53; RITUXIMAB;

EID: 10044244889     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.10362     Document Type: Review
Times cited : (4)

References (212)
  • 2
    • 0036791008 scopus 로고    scopus 로고
    • p53 and DNA damage-inducible expression of the xeroderma pigmentosum group C gene
    • Adimoolam S, Ford JM. 2002. p53 and DNA damage-inducible expression of the xeroderma pigmentosum group C gene. Proc Natl Acad Sci USA 99:12985-12990.
    • (2002) Proc Natl Acad Sci USA , vol.99 , pp. 12985-12990
    • Adimoolam, S.1    Ford, J.M.2
  • 5
    • 1642398622 scopus 로고    scopus 로고
    • Interpretation of p53 immunoreactivity in endometrial carcinoma: Establishing a clinically relevant cut-off level
    • Alkushi A, Lim P, Coldman A, Huntsman D, Miller D, Gilks CB. 2004. Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level, Int J Gynecol Pathol 23:129-137.
    • (2004) Int J Gynecol Pathol , vol.23 , pp. 129-137
    • Alkushi, A.1    Lim, P.2    Coldman, A.3    Huntsman, D.4    Miller, D.5    Gilks, C.B.6
  • 6
    • 0032735232 scopus 로고    scopus 로고
    • Survivin apoptosis: An interloper between cell death and cell proliferation in cancer
    • Altieri DC, Marchisio C. 1999. Survivin apoptosis: an interloper between cell death and cell proliferation in cancer. Lab Invest 79:1327-1333.
    • (1999) Lab Invest , vol.79 , pp. 1327-1333
    • Altieri, D.C.1    Marchisio, C.2
  • 7
    • 0030746636 scopus 로고    scopus 로고
    • A novel anti-apoptotic gene, survivin, expressed in cancer and lymphoma
    • Ambrosini G, Adida C, Altieri DC. 1997. A novel anti-apoptotic gene, survivin, expressed in cancer and lymphoma. Nat Med 3:917-921.
    • (1997) Nat Med , vol.3 , pp. 917-921
    • Ambrosini, G.1    Adida, C.2    Altieri, D.C.3
  • 11
    • 0038418869 scopus 로고    scopus 로고
    • Chk1 and Chk2 kinases in checkpoint control and cancer
    • Bartek J, Lukas J. 2003. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 3:421-429.
    • (2003) Cancer Cell , vol.3 , pp. 421-429
    • Bartek, J.1    Lukas, J.2
  • 15
    • 0037220165 scopus 로고    scopus 로고
    • The UMD-p53 database: New mutations and analysis tools
    • Berond C, Soussi T. 2003. The UMD-p53 database: new mutations and analysis tools. Hum Mutat 21:176-181.
    • (2003) Hum Mutat , vol.21 , pp. 176-181
    • Berond, C.1    Soussi, T.2
  • 16
    • 0033552948 scopus 로고    scopus 로고
    • Mutant p53 gain of function: Differential effects of different p53 mutants on resistance of cultured cells to chemotherapy
    • Blandino G, Levine AJ, Oren M. 1999. Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 18:477-485.
    • (1999) Oncogene , vol.18 , pp. 477-485
    • Blandino, G.1    Levine, A.J.2    Oren, M.3
  • 17
    • 3042838562 scopus 로고    scopus 로고
    • Selective inhibition of the DNA-dependent protein kinase (DNA-PK) by the radiosensitizing agent caffeine
    • Block WD, Merkle D, Meek K, Lees-Miller SP. 2004. Selective inhibition of the DNA-dependent protein kinase (DNA-PK) by the radiosensitizing agent caffeine. Nucleic Acids Res 32:1967-1972.
    • (2004) Nucleic Acids Res , vol.32 , pp. 1967-1972
    • Block, W.D.1    Merkle, D.2    Meek, K.3    Lees-Miller, S.P.4
  • 19
    • 0031929626 scopus 로고    scopus 로고
    • TP53 and long-term prognosis in colorectal cancer: Mutations in the L3 zinc-binding domain predict poor survival
    • Borresen-Dale AL, Lothe RA, Meling GI, Hainaut P, Rognum TO, Skovlund E. 1998. TP53 and long-term prognosis in colorectal cancer: mutations in the L3 zinc-binding domain predict poor survival. Clin Cancer Res 4:203-210.
    • (1998) Clin Cancer Res , vol.4 , pp. 203-210
    • Borresen-Dale, A.L.1    Lothe, R.A.2    Meling, G.I.3    Hainaut, P.4    Rognum, T.O.5    Skovlund, E.6
  • 20
    • 0034674901 scopus 로고    scopus 로고
    • A family of drug transporters: The multidrug resistance-associated proteins
    • Borst P, Evers R, Kool M, Wijnholds J. 2000. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 92:1295-1302.
    • (2000) J Natl Cancer Inst , vol.92 , pp. 1295-1302
    • Borst, P.1    Evers, R.2    Kool, M.3    Wijnholds, J.4
  • 24
    • 0034671556 scopus 로고    scopus 로고
    • Preferential retention of codon 72 arginine p53 in squamous cell carcinomas of the vulva occurs in cancers positive and negative for human papillomavirus
    • Brooks LA, Tidy JA, Gusterson B, Hiller L, O'Nions J, Gasco M, Marin MC, Farrell PJ, Kaelin WG Jr, Crook T. 2000. Preferential retention of codon 72 arginine p53 in squamous cell carcinomas of the vulva occurs in cancers positive and negative for human papillomavirus. Cancer Res 60:6875-6877.
    • (2000) Cancer Res , vol.60 , pp. 6875-6877
    • Brooks, L.A.1    Tidy, J.A.2    Gusterson, B.3    Hiller, L.4    O'Nions, J.5    Gasco, M.6    Marin, M.C.7    Farrell, P.J.8    Kaelin Jr., W.G.9    Crook, T.10
  • 25
    • 0023709002 scopus 로고
    • A variation in the structure of the protein-coding region of the human p53 gene
    • Buchman VL, Chumakov PM, Ninkina NN, Samarina OP, Georgiev GP. 1988. A variation in the structure of the protein-coding region of the human p53 gene. Gene 70:245-252.
    • (1988) Gene , vol.70 , pp. 245-252
    • Buchman, V.L.1    Chumakov, P.M.2    Ninkina, N.N.3    Samarina, O.P.4    Georgiev, G.P.5
  • 29
    • 0142058248 scopus 로고    scopus 로고
    • Small molecules that reactivate mutant p53
    • Bykov VJ, Selivanova G, Wiman KG. 2003. Small molecules that reactivate mutant p53. Eur J Cancer 39:1828-1834.
    • (2003) Eur J Cancer , vol.39 , pp. 1828-1834
    • Bykov, V.J.1    Selivanova, G.2    Wiman, K.G.3
  • 30
    • 0035904394 scopus 로고    scopus 로고
    • The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth
    • Cadwell C, Zambetti GP. 2001. The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth. Gene 277:15-30.
    • (2001) Gene , vol.277 , pp. 15-30
    • Cadwell, C.1    Zambetti, G.P.2
  • 32
    • 0037317840 scopus 로고    scopus 로고
    • Inhibiting the p53-MDM2 interaction: An important target for cancer therapy
    • Chene P. 2003. Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nature Rev Cancer 3:102-109.
    • (2003) Nature Rev Cancer , vol.3 , pp. 102-109
    • Chene, P.1
  • 33
    • 0031427453 scopus 로고    scopus 로고
    • Biological and clinical significance of concurrent p53 gene alterations, MDR1 gene expression, and S-phase fraction analyses in breast cancer patients treated with primary chemotherapy or radiotherapy
    • Chevillard S, Lebeau J, Pouillart P, de Toma C, Beldjord C, Asselain B, Klijanienko J, Fourquet A, Magdelenat H, Vielh P. 1997. Biological and clinical significance of concurrent p53 gene alterations, MDR1 gene expression, and S-phase fraction analyses in breast cancer patients treated with primary chemotherapy or radiotherapy. Clin Cancer Res 3:2471-2478.
    • (1997) Clin Cancer Res , vol.3 , pp. 2471-2478
    • Chevillard, S.1    Lebeau, J.2    Pouillart, P.3    De Toma, C.4    Beldjord, C.5    Asselain, B.6    Klijanienko, J.7    Fourquet, A.8    Magdelenat, H.9    Vielh, P.10
  • 34
    • 0027983669 scopus 로고
    • Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations
    • Cho Y, Gorina S, Jeffrey PD, Pavletich NP. 1994. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265:346-355.
    • (1994) Science , vol.265 , pp. 346-355
    • Cho, Y.1    Gorina, S.2    Jeffrey, P.D.3    Pavletich, N.P.4
  • 35
    • 0037326291 scopus 로고    scopus 로고
    • Ribozyme-mediated cleavage of the human survivin mRNA and inhibition of antiapoptotic function of survivin in MCF-7 cells
    • Choi KS, Lee TH, Jung MH. 2003. Ribozyme-mediated cleavage of the human survivin mRNA and inhibition of antiapoptotic function of survivin in MCF-7 cells. Cancer Gene Ther 10:87-95.
    • (2003) Cancer Gene Ther , vol.10 , pp. 87-95
    • Choi, K.S.1    Lee, T.H.2    Jung, M.H.3
  • 37
    • 1542299064 scopus 로고    scopus 로고
    • Evaluation of oligonucleotide arrays for sequencing of the p53 gene in DNA from formalin-fixed, paraffin-embedded breast cancer specimens
    • Cooper M, Li SQ, Bhardwaj T, Rohan T, Kandel RA. 2004. Evaluation of oligonucleotide arrays for sequencing of the p53 gene in DNA from formalin-fixed, paraffin-embedded breast cancer specimens. Clin Chem 50:500-508.
    • (2004) Clin Chem , vol.50 , pp. 500-508
    • Cooper, M.1    Li, S.Q.2    Bhardwaj, T.3    Rohan, T.4    Kandel, R.A.5
  • 39
    • 0345256634 scopus 로고    scopus 로고
    • The role of p53 in chemosensitivity and radiosensitivity
    • El-Deiry WS. 2003. The role of p53 in chemosensitivity and radiosensitivity. Oncogene 22:7486-7495.
    • (2003) Oncogene , vol.22 , pp. 7486-7495
    • El-Deiry, W.S.1
  • 40
    • 1242297013 scopus 로고    scopus 로고
    • Prognostic value of p53 and MDM2 expression in bilharziasis-associated squamous cell carcinoma of the urinary bladder
    • El-Kenawy A-M, El-Kott AF, Khalil AM. 2003. Prognostic value of p53 and MDM2 expression in bilharziasis-associated squamous cell carcinoma of the urinary bladder. Int J Biol Markers 18:284-289.
    • (2003) Int J Biol Markers , vol.18 , pp. 284-289
    • El-Kenawy, A.-M.1    El-Kott, A.F.2    Khalil, A.M.3
  • 41
    • 0029155714 scopus 로고
    • Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer
    • Elledge RM, Gray R, Mansour E, Yu Y, Clark GM, Ravdin P, Osborne CK, Gilchrist K, Davidson NE, Robert N, et al. 1995. Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer. J Natl Cancer Inst 87:1254-1256.
    • (1995) J Natl Cancer Inst , vol.87 , pp. 1254-1256
    • Elledge, R.M.1    Gray, R.2    Mansour, E.3    Yu, Y.4    Clark, G.M.5    Ravdin, P.6    Osborne, C.K.7    Gilchrist, K.8    Davidson, N.E.9    Robert, N.10
  • 42
    • 0034254821 scopus 로고    scopus 로고
    • Can p53 alterations be used to predict tumour response to pre-operative chemo-radiotherapy in locally advanced rectal cancer?
    • Elsaleh H, Robbins P, Joseph D, Powell B, Grieu F, Menso L, Iacopetta B. 2000. Can p53 alterations be used to predict tumour response to pre-operative chemo-radiotherapy in locally advanced rectal cancer? Radiother Oncol 56:239-244.
    • (2000) Radiother Oncol , vol.56 , pp. 239-244
    • Elsaleh, H.1    Robbins, P.2    Joseph, D.3    Powell, B.4    Grieu, F.5    Menso, L.6    Iacopetta, B.7
  • 43
    • 0032473823 scopus 로고    scopus 로고
    • TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer
    • Erber B, Conradt C, Homann N, Enders C, Finekh M, Dietz A, Weidauer H, Bosch FX. 1998. TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer. Oncogene 16:1671-1679.
    • (1998) Oncogene , vol.16 , pp. 1671-1679
    • Erber, B.1    Conradt, C.2    Homann, N.3    Enders, C.4    Finekh, M.5    Dietz, A.6    Weidauer, H.7    Bosch, F.X.8
  • 44
    • 0025312728 scopus 로고
    • A genetic model for colorectal tumorigenesis
    • Fearon ER, Vogelstein B. 1990. A genetic model for colorectal tumorigenesis. Cell 61:759-767.
    • (1990) Cell , vol.61 , pp. 759-767
    • Fearon, E.R.1    Vogelstein, B.2
  • 45
    • 0037152679 scopus 로고    scopus 로고
    • Increased sensitivity of p53-deficient cells to anticancer agents due to loss of Pms2
    • Fedier A, Ruefenacht UB, Schwarz VA, Haller U, Fink D. 2002. Increased sensitivity of p53-deficient cells to anticancer agents due to loss of Pms2. Br J Cancer 87:1027-1033.
    • (2002) Br J Cancer , vol.87 , pp. 1027-1033
    • Fedier, A.1    Ruefenacht, U.B.2    Schwarz, V.A.3    Haller, U.4    Fink, D.5
  • 46
    • 3142675287 scopus 로고    scopus 로고
    • p53-deficient cells display increased sensitivity to anthracyclines after loss of the catalytic subunit of the DNA-dependent protein kinase
    • Fedier A, Moawad A, Haller U, Fink D. 2003a. p53-deficient cells display increased sensitivity to anthracyclines after loss of the catalytic subunit of the DNA-dependent protein kinase. Int J Oncol 23:1431-1437.
    • (2003) Int J Oncol , vol.23 , pp. 1431-1437
    • Fedier, A.1    Moawad, A.2    Haller, U.3    Fink, D.4
  • 47
    • 0038011619 scopus 로고    scopus 로고
    • Loss of arm sensitises p53-deficient cells to topoisomerase poisons and antimetabolites
    • Fedier A, Schlamminger M, Schwarz VA, Haller U, Howell SB, Fink D. 2003b. Loss of arm sensitises p53-deficient cells to topoisomerase poisons and antimetabolites. Ann Oncol 14:938-945.
    • (2003) Ann Oncol , vol.14 , pp. 938-945
    • Fedier, A.1    Schlamminger, M.2    Schwarz, V.A.3    Haller, U.4    Howell, S.B.5    Fink, D.6
  • 48
    • 0043130465 scopus 로고    scopus 로고
    • The effect of loss of Brea1 on the sensitivity to anticancer agents in p53-deficient cells
    • Fedier A, Steiner RA, Schwarz VA, Lenherr L, Haller U, Fink D. 2003c. The effect of loss of Brea1 on the sensitivity to anticancer agents in p53-deficient cells. Int J Oncol 22:1169-1173.
    • (2003) Int J Oncol , vol.22 , pp. 1169-1173
    • Fedier, A.1    Steiner, R.A.2    Schwarz, V.A.3    Lenherr, L.4    Haller, U.5    Fink, D.6
  • 50
    • 0036269099 scopus 로고    scopus 로고
    • Evaluation of the tissue microarray technique for immunohistochemical analysis in rectal cancer
    • Fernebro E, Dictor M, Bendahl PO, Ferno M, Nilbert M. 2002. Evaluation of the tissue microarray technique for immunohistochemical analysis in rectal cancer. Arch Pathol Lab Med 126:702-705.
    • (2002) Arch Pathol Lab Med , vol.126 , pp. 702-705
    • Fernebro, E.1    Dictor, M.2    Bendahl, P.O.3    Ferno, M.4    Nilbert, M.5
  • 52
    • 0842265105 scopus 로고    scopus 로고
    • p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer
    • Fondevila C, Metges JP, Fuster J, Grau JJ, Palacin A, Castells A, Volant A, Pera M. 2004. p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer. Br J Cancer 90:206-215.
    • (2004) Br J Cancer , vol.90 , pp. 206-215
    • Fondevila, C.1    Metges, J.P.2    Fuster, J.3    Grau, J.J.4    Palacin, A.5    Castells, A.6    Volant, A.7    Pera, M.8
  • 53
    • 0033601370 scopus 로고    scopus 로고
    • Pharmacological rescue of mutant p53 conformation and function
    • Foster BA, Coffey HA, Morin MJ, Rastinejad F. 1999. Pharmacological rescue of mutant p53 conformation and function. Science 286:2507-2510.
    • (1999) Science , vol.286 , pp. 2507-2510
    • Foster, B.A.1    Coffey, H.A.2    Morin, M.J.3    Rastinejad, F.4
  • 56
    • 0344198117 scopus 로고    scopus 로고
    • TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer
    • Geisler S, Borresen-Dale AL, Johnsen H, Aas T, Geisler J, Akslen LA, Anker G, Lonning PE. 2003. TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. Clin Cancer Res 9:5582-5588.
    • (2003) Clin Cancer Res , vol.9 , pp. 5582-5588
    • Geisler, S.1    Borresen-Dale, A.L.2    Johnsen, H.3    Aas, T.4    Geisler, J.5    Akslen, L.A.6    Anker, G.7    Lonning, P.E.8
  • 57
    • 0037303255 scopus 로고    scopus 로고
    • Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-Year follow up data
    • Goffin JR, Chappuis PO, Begin LR, Wong N, Brunet JS, Hamel N, Paradis AJ, Boyd J, Foulkes WD. 2003. Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data. Cancer 97:527-536.
    • (2003) Cancer , vol.97 , pp. 527-536
    • Goffin, J.R.1    Chappuis, P.O.2    Begin, L.R.3    Wong, N.4    Brunet, J.S.5    Hamel, N.6    Paradis, A.J.7    Boyd, J.8    Foulkes, W.D.9
  • 58
    • 0028939453 scopus 로고
    • Wild type p53 stimulates expression from the human multidrug resistance promoter in a p53-negative cell line
    • Goldsmith ME, Gridas JM, Schneider E, Cowan KH. 1995. Wild type p53 stimulates expression from the human multidrug resistance promoter in a p53-negative cell line. J Biol Chem. 270:1894-1898.
    • (1995) J Biol Chem , vol.270 , pp. 1894-1898
    • Goldsmith, M.E.1    Gridas, J.M.2    Schneider, E.3    Cowan, K.H.4
  • 59
    • 0842327294 scopus 로고    scopus 로고
    • Simultaneous mutations in K-ras and TP53 are indicative of poor prognosis in sporadic colorectal cancer
    • Gonzalez-Aguilera JJ, Oliart S, Azcoita MM, Fernandez-Peralta AM. 2004. Simultaneous mutations in K-ras and TP53 are indicative of poor prognosis in sporadic colorectal cancer. Am J Clin Oncol 27:39-45.
    • (2004) Am J Clin Oncol , vol.27 , pp. 39-45
    • Gonzalez-Aguilera, J.J.1    Oliart, S.2    Azcoita, M.M.3    Fernandez-Peralta, A.M.4
  • 60
    • 0346362405 scopus 로고    scopus 로고
    • Validation of tissue microarrays using p53 immunohistochemical studies of squamous cell carcinoma of the larynx
    • Griffin MC, Robinson RA, Trask DK. 2003. Validation of tissue microarrays using p53 immunohistochemical studies of squamous cell carcinoma of the larynx. Mod Pathol 16:1181-1188.
    • (2003) Mod Pathol , vol.16 , pp. 1181-1188
    • Griffin, M.C.1    Robinson, R.A.2    Trask, D.K.3
  • 61
    • 0033397882 scopus 로고    scopus 로고
    • Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma
    • Grossman D, McNiff JM, Li F, Altieri DC. 1999. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol 113:1076-1081.
    • (1999) J Invest Dermatol , vol.113 , pp. 1076-1081
    • Grossman, D.1    McNiff, J.M.2    Li, F.3    Altieri, D.C.4
  • 62
  • 63
    • 0037317521 scopus 로고    scopus 로고
    • The role of p53 in determining sensitivity to radiotherapy
    • Gudkov AV, Komarova EA. 2003. The role of p53 in determining sensitivity to radiotherapy. Nat Rev Cancer 3:117-129.
    • (2003) Nat Rev Cancer , vol.3 , pp. 117-129
    • Gudkov, A.V.1    Komarova, E.A.2
  • 64
    • 0034295214 scopus 로고    scopus 로고
    • Transfer of p14ARF gene in drug-resistant human breast cancer MCF-7/Adr cells inhibits proliferation and reduces doxorubicin resistance
    • Guo-Chang F, Chu-Tse W. 2000. Transfer of p14ARF gene in drug-resistant human breast cancer MCF-7/Adr cells inhibits proliferation and reduces doxorubicin resistance. Cancer Lett 158:203-210.
    • (2000) Cancer Lett , vol.158 , pp. 203-210
    • Guo-Chang, F.1    Chu-Tse, W.2
  • 65
    • 0032990031 scopus 로고    scopus 로고
    • Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer
    • Gurnani M, Lipari P, Dell J, Shi B, Nielsen LL. 1999. Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer. Cancer Chemother Pharmacol 44:143-151.
    • (1999) Cancer Chemother Pharmacol , vol.44 , pp. 143-151
    • Gurnani, M.1    Lipari, P.2    Dell, J.3    Shi, B.4    Nielsen, L.L.5
  • 66
    • 0033992478 scopus 로고    scopus 로고
    • p53 and human cancer: The first ten thousand mutations
    • Hainaut P, Hollstein M. 2000. p53 and human cancer: the first ten thousand mutations. Adv Cancer Res 77:81-137.
    • (2000) Adv Cancer Res , vol.77 , pp. 81-137
    • Hainaut, P.1    Hollstein, M.2
  • 67
    • 0038824021 scopus 로고    scopus 로고
    • Predictive value of expression of P53, Bcl-2 and lung resistance-related protein for response to chemotherapy in non-small cell lung cancers
    • Harada T, Ogura S, Yamazaki K, Kinoshita I, Itoh T, Isobe H, Yamashiro K, Dosaka-Akita H, Nishimura M. 2003. Predictive value of expression of P53, Bcl-2 and lung resistance-related protein for response to chemotherapy in non-small cell lung cancers. Cancer Sci 94:394-399.
    • (2003) Cancer Sci , vol.94 , pp. 394-399
    • Harada, T.1    Ogura, S.2    Yamazaki, K.3    Kinoshita, I.4    Itoh, T.5    Isobe, H.6    Yamashiro, K.7    Dosaka-Akita, H.8    Nishimura, M.9
  • 68
    • 0028842340 scopus 로고
    • A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice
    • Harvey M, Vogel H, Morris D, Bradley A, Bernstein A, Donehower LA. 1995. A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice. Nat Genet 9:305-311.
    • (1995) Nat Genet , vol.9 , pp. 305-311
    • Harvey, M.1    Vogel, H.2    Morris, D.3    Bradley, A.4    Bernstein, A.5    Donehower, L.A.6
  • 71
    • 0030905284 scopus 로고    scopus 로고
    • Mdm2 promotes the rapid degradation of p53
    • Haupt Y, Maya R, Kazaz A, Oren M. 1997. Mdm2 promotes the rapid degradation of p53. Nature 387:296-299.
    • (1997) Nature , vol.387 , pp. 296-299
    • Haupt, Y.1    Maya, R.2    Kazaz, A.3    Oren, M.4
  • 74
    • 0036479115 scopus 로고    scopus 로고
    • Transcriptional repression of the anti-apoptotic survivin gene by wild type p53
    • Hoffman WH, Biade S, Zilfon JT, Chen J, Murphy M. 2002. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 277:3247-3257.
    • (2002) J Biol Chem , vol.277 , pp. 3247-3257
    • Hoffman, W.H.1    Biade, S.2    Zilfon, J.T.3    Chen, J.4    Murphy, M.5
  • 76
    • 0033521621 scopus 로고    scopus 로고
    • Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53
    • Honda R, Yasuda H. 1999. Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J 18:22-27.
    • (1999) EMBO J , vol.18 , pp. 22-27
    • Honda, R.1    Yasuda, H.2
  • 77
    • 0031583962 scopus 로고    scopus 로고
    • Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53
    • Honda K, Tanaka H, Yasuda H. 1997. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 420:25-27.
    • (1997) FEBS Lett , vol.420 , pp. 25-27
    • Honda, K.1    Tanaka, H.2    Yasuda, H.3
  • 81
    • 0033958086 scopus 로고    scopus 로고
    • Multiple physiological functions for multidrug transporter P-glycoprotein?
    • Johnstone RW, Ruefli AA, Smyth MJ. 2000. Multiple physiological functions for multidrug transporter P-glycoprotein? Trends Biochem Sci 25:1-6.
    • (2000) Trends Biochem Sci , vol.25 , pp. 1-6
    • Johnstone, R.W.1    Ruefli, A.A.2    Smyth, M.J.3
  • 82
    • 0034324572 scopus 로고    scopus 로고
    • UCN-01 and camptothecin induce DNA double-strand breaks in p53 mutant tumor cells, but not in normal or p53 negative epithelial cells
    • Jones CB, Clements MK, Redkar A, Daoud SS. 2000. UCN-01 and camptothecin induce DNA double-strand breaks in p53 mutant tumor cells, but not in normal or p53 negative epithelial cells. Int J Oncol 17:1043-1051.
    • (2000) Int J Oncol , vol.17 , pp. 1043-1051
    • Jones, C.B.1    Clements, M.K.2    Redkar, A.3    Daoud, S.S.4
  • 83
  • 84
    • 0027501841 scopus 로고
    • Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene
    • Juven T, Barak Y, Zauberman A, George DL, Oren M. 1993. Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. Oncogene 8:3411-3416.
    • (1993) Oncogene , vol.8 , pp. 3411-3416
    • Juven, T.1    Barak, Y.2    Zauberman, A.3    George, D.L.4    Oren, M.5
  • 85
    • 0035138823 scopus 로고    scopus 로고
    • p53 induction and apoptosis in response to radio- and chemotherapy in vivo is tumor-type-dependent
    • Kemp CJ, Sun S, Gurley KE. 2001. p53 induction and apoptosis in response to radio- and chemotherapy in vivo is tumor-type-dependent. Cancer Res 61:327-332.
    • (2001) Cancer Res , vol.61 , pp. 327-332
    • Kemp, C.J.1    Sun, S.2    Gurley, K.E.3
  • 87
    • 0041833667 scopus 로고    scopus 로고
    • Pyrazoloacridine is active in multidrug-resistant neuroblastoma cell lines with nonfunctional p53
    • Keshelava N, Tsao-Wei D, Reynolds CP. 2003. Pyrazoloacridine is active in multidrug-resistant neuroblastoma cell lines with nonfunctional p53. Clin Cancer Res 9:3492-3502.
    • (2003) Clin Cancer Res , vol.9 , pp. 3492-3502
    • Keshelava, N.1    Tsao-Wei, D.2    Reynolds, C.P.3
  • 88
    • 0028057398 scopus 로고
    • High frequency of allelic deletion on chromosome 17p in advanced colorectal cancer
    • Khine K, Smith DR, Goh HS. 1994. High frequency of allelic deletion on chromosome 17p in advanced colorectal cancer. Cancer 73:28-35.
    • (1994) Cancer , vol.73 , pp. 28-35
    • Khine, K.1    Smith, D.R.2    Goh, H.S.3
  • 89
  • 90
    • 0034108062 scopus 로고    scopus 로고
    • Negative p53/positive p21 immunostaining is a predictor of favorable response to chemotherapy in patients with locally advanced bladder cancer
    • Koga F, Kitahara S, Arai K, Honda M, Sumi S, Yoshida K. 2000. Negative p53/positive p21 immunostaining is a predictor of favorable response to chemotherapy in patients with locally advanced bladder cancer. Jpn J Cancer Res 91:416-423.
    • (2000) Jpn J Cancer Res , vol.91 , pp. 416-423
    • Koga, F.1    Kitahara, S.2    Arai, K.3    Honda, M.4    Sumi, S.5    Yoshida, K.6
  • 91
    • 0035829685 scopus 로고    scopus 로고
    • Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells
    • Komaras K, Cuddihy AR, Christopoulos H, Hogg A, O'Connell MJ. 2001. Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells. Oncogene 20:7453-7463.
    • (2001) Oncogene , vol.20 , pp. 7453-7463
    • Komaras, K.1    Cuddihy, A.R.2    Christopoulos, H.3    Hogg, A.4    O'Connell, M.J.5
  • 93
    • 0942301261 scopus 로고    scopus 로고
    • Spectrum of p53 tumor suppressor gene mutations and breast cancer survival
    • Lai H, Ma F, Trapido E, Meng L, Lai S. 2004. Spectrum of p53 tumor suppressor gene mutations and breast cancer survival. Breast Cancer Res Treat 83:57-66.
    • (2004) Breast Cancer Res Treat , vol.83 , pp. 57-66
    • Lai, H.1    Ma, F.2    Trapido, E.3    Meng, L.4    Lai, S.5
  • 96
    • 0742317835 scopus 로고    scopus 로고
    • Distinct subtypes of serous ovarian carcinoma identified by p53 determination
    • Lassus H, Leminen A, Luudin J, Lehtovirta P, Butzow R. 2003. Distinct subtypes of serous ovarian carcinoma identified by p53 determination. Gynecol Oncol 91:504-512.
    • (2003) Gynecol Oncol , vol.91 , pp. 504-512
    • Lassus, H.1    Leminen, A.2    Luudin, J.3    Lehtovirta, P.4    Butzow, R.5
  • 98
    • 0042023334 scopus 로고    scopus 로고
    • Expression of p53, pRB, and p16 in lung tumours: A validation study on tissue microarravs
    • Leversha MA, Fielding P, Watson S, Gosney JR, Field JK. 2003. Expression of p53, pRB, and p16 in lung tumours: a validation study on tissue microarravs. J Pathol 200:610-619.
    • (2003) J Pathol , vol.200 , pp. 610-619
    • Leversha, M.A.1    Fielding, P.2    Watson, S.3    Gosney, J.R.4    Field, J.K.5
  • 99
    • 0031691792 scopus 로고    scopus 로고
    • Quantitative analysis of p53 protein in non-small cell lung cancer and its prognostic value
    • Levesque MA, D'Costa M, Spratt EH, Yaman MM, Diamandis EP. 1998. Quantitative analysis of p53 protein in non-small cell lung cancer and its prognostic value. Int J Cancer 79:494-501.
    • (1998) Int J Cancer , vol.79 , pp. 494-501
    • Levesque, M.A.1    D'Costa, M.2    Spratt, E.H.3    Yaman, M.M.4    Diamandis, E.P.5
  • 100
    • 0036466874 scopus 로고    scopus 로고
    • p53 overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection
    • Liang J-T, Huang K-C, Cheng Y-M, Hsu H-C, Cheng A-L, Hsu C-H, Yeb K-H, Wang S-M, Chang K-J. 2002. p53 overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection. Int J Cancer 97:451-457.
    • (2002) Int J Cancer , vol.97 , pp. 451-457
    • Liang, J.-T.1    Huang, K.-C.2    Cheng, Y.-M.3    Hsu, H.-C.4    Cheng, A.-L.5    Hsu, C.-H.6    Yeb, K.-H.7    Wang, S.-M.8    Chang, K.-J.9
  • 101
    • 0035866361 scopus 로고    scopus 로고
    • P53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin
    • Lin X, Ramamurthi K, Mishima M, Kondo A, Christen RD, Howell SB. 2001. P53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin. Cancer Res 61:1508-1516.
    • (2001) Cancer Res , vol.61 , pp. 1508-1516
    • Lin, X.1    Ramamurthi, K.2    Mishima, M.3    Kondo, A.4    Christen, R.D.5    Howell, S.B.6
  • 103
    • 0030015546 scopus 로고    scopus 로고
    • p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancer
    • Linn SC, Honkoop AH, Hoekman K, van der Valk P, Pinedo HM, Giaccone G. 1996. p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancer. Br J Cancer 74:63-68.
    • (1996) Br J Cancer , vol.74 , pp. 63-68
    • Linn, S.C.1    Honkoop, A.H.2    Hoekman, K.3    Van Der Valk, P.4    Pinedo, H.M.5    Giaccone, G.6
  • 106
    • 0141743327 scopus 로고    scopus 로고
    • Differential effects of cell cycle regulatory protein p21 on apoptosis and sensitivity to cancer chemotherapy
    • Liu S, Bishop WR, Lin M. 2003. Differential effects of cell cycle regulatory protein p21 on apoptosis and sensitivity to cancer chemotherapy. Drug Resist Updat 6:183-195.
    • (2003) Drug Resist Updat , vol.6 , pp. 183-195
    • Liu, S.1    Bishop, W.R.2    Lin, M.3
  • 109
    • 0032484084 scopus 로고    scopus 로고
    • Linkage of ATM to cell cycle regulation by the Chk2 protein kinase
    • Matsuoka S, Huang M, Elledge SJ. 1998. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 282:1893-1897.
    • (1998) Science , vol.282 , pp. 1893-1897
    • Matsuoka, S.1    Huang, M.2    Elledge, S.J.3
  • 111
    • 0037085271 scopus 로고    scopus 로고
    • PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy
    • Mayo LD, Dixon JE, Durden DL, Tonks NK, Donner DB. 2002. PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J Biol Chem 277:5484-5489.
    • (2002) J Biol Chem , vol.277 , pp. 5484-5489
    • Mayo, L.D.1    Dixon, J.E.2    Durden, D.L.3    Tonks, N.K.4    Donner, D.B.5
  • 115
    • 0033765491 scopus 로고    scopus 로고
    • Prognostic significance of p53 alterations in patients with non-small cell lung cancer: A meta-analysis
    • Mitsudomi T, Hamajima N, Ogawa M, Takahashi T. 2000. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin Cancer Res 6:4055-1063.
    • (2000) Clin Cancer Res , vol.6 , pp. 4055-1063
    • Mitsudomi, T.1    Hamajima, N.2    Ogawa, M.3    Takahashi, T.4
  • 117
    • 0033959744 scopus 로고    scopus 로고
    • MDM2-master regulator of the p53 tumor suppressor protein
    • Momand J, Wu HH, Dasgupta G. 2000. MDM2-master regulator of the p53 tumor suppressor protein. Gene 242:15-29.
    • (2000) Gene , vol.242 , pp. 15-29
    • Momand, J.1    Wu, H.H.2    Dasgupta, G.3
  • 118
    • 0030625476 scopus 로고    scopus 로고
    • The use of biomarkers to study pathogenesis and mechanisms of cancer: Oesophagus and skin cancer as models
    • Montesano R, Hainaut P, Hall J. 1997. The use of biomarkers to study pathogenesis and mechanisms of cancer: oesophagus and skin cancer as models. IARC Sci Publ 142:291-301.
    • (1997) IARC Sci Publ , vol.142 , pp. 291-301
    • Montesano, R.1    Hainaut, P.2    Hall, J.3
  • 119
    • 0029564410 scopus 로고
    • Proliferative activity in breast carcinoma evaluated by BrdU and PCNA. Correlation with expression of p53, c-erbB-2, estrogen receptor and P-glycoprotein
    • Moriki T, Takahashi T, Tanioka F, Yamane T, Hara H. 1995. Proliferative activity in breast carcinoma evaluated by BrdU and PCNA. Correlation with expression of p53, c-erbB-2, estrogen receptor and P-glycoprotein. Pathol Res Pract 191:1122-1132.
    • (1995) Pathol Res Pract , vol.191 , pp. 1122-1132
    • Moriki, T.1    Takahashi, T.2    Tanioka, F.3    Yamane, T.4    Hara, H.5
  • 120
    • 0029803281 scopus 로고    scopus 로고
    • Wild-type p53 negatively regulates the expression of a microtubule-associated protein
    • Murphy M, Hinman A, Levine AJ. 1996. Wild-type p53 negatively regulates the expression of a microtubule-associated protein. Genes Dev 10:2971-2980.
    • (1996) Genes Dev , vol.10 , pp. 2971-2980
    • Murphy, M.1    Hinman, A.2    Levine, A.J.3
  • 122
    • 0028109125 scopus 로고
    • Transactivation of the human multidrug resistance (MDR1) gene promoter by p53 mutants
    • Nguyen KT, Liu B, Ueda K, Gottesman MM, Pastan I, Chin KV. 1994. Transactivation of the human multidrug resistance (MDR1) gene promoter by p53 mutants. Oncol Res 6:71-77.
    • (1994) Oncol Res , vol.6 , pp. 71-77
    • Nguyen, K.T.1    Liu, B.2    Ueda, K.3    Gottesman, M.M.4    Pastan, I.5    Chin, K.V.6
  • 123
    • 0031944077 scopus 로고    scopus 로고
    • Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer
    • Nielsen LL, Lipari P, Dell J, Curnani M, Hajian G. 1998. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer. Clin Cancer Res 4:835-846.
    • (1998) Clin Cancer Res , vol.4 , pp. 835-846
    • Nielsen, L.L.1    Lipari, P.2    Dell, J.3    Curnani, M.4    Hajian, G.5
  • 124
    • 0034141471 scopus 로고    scopus 로고
    • Mechanism of rescue of common p53 cancer mutations by second-site suppressor mutations
    • Nikolova PV, Wong KB, DeDecker B, Henckel J, Fersht AR. 2000. Mechanism of rescue of common p53 cancer mutations by second-site suppressor mutations. EMBO J 19:370-378.
    • (2000) EMBO J , vol.19 , pp. 370-378
    • Nikolova, P.V.1    Wong, K.B.2    DeDecker, B.3    Henckel, J.4    Fersht, A.R.5
  • 126
    • 0342657718 scopus 로고    scopus 로고
    • A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy
    • Olie RA, Simoes-Wust AP, Banmann B, Leech SH, Fabbro D, Stahel RA, Zangemeister-Wittke U. 2000. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res 60:2805-2809.
    • (2000) Cancer Res , vol.60 , pp. 2805-2809
    • Olie, R.A.1    Simoes-Wust, A.P.2    Banmann, B.3    Leech, S.H.4    Fabbro, D.5    Stahel, R.A.6    Zangemeister-Wittke, U.7
  • 127
    • 0036258111 scopus 로고    scopus 로고
    • The IARC TP53 database: New online mutation analysis and recommendations to users
    • Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainant P. 2002. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 19:607-614.
    • (2002) Hum Mutat , vol.19 , pp. 607-614
    • Olivier, M.1    Eeles, R.2    Hollstein, M.3    Khan, M.A.4    Harris, C.C.5    Hainant, P.6
  • 128
    • 0030448760 scopus 로고    scopus 로고
    • Cytoplasmically sequestered wild-type p53 protein in neuroblastoma is relocated to the nucleus by a C-terminal peptide
    • Ostermeyer AG, Runko E, Winkfield B, Ahn B, Moll UM. 1996. Cytoplasmically sequestered wild-type p53 protein in neuroblastoma is relocated to the nucleus by a C-terminal peptide. Proc Natl Acad Sci U S A 93:15190-15194.
    • (1996) Proc Natl Acad Sci U S A , vol.93 , pp. 15190-15194
    • Ostermeyer, A.G.1    Runko, E.2    Winkfield, B.3    Ahn, B.4    Moll, U.M.5
  • 129
    • 0025748539 scopus 로고
    • p53 mutation in hepatocellular carcinoma after aflatoxin exposure
    • Ozturk M. 1991. p53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet 338:1356-1359.
    • (1991) Lancet , vol.338 , pp. 1356-1359
    • Ozturk, M.1
  • 130
    • 0037152688 scopus 로고    scopus 로고
    • Association of p53 codon 72 polymorphism with advanced lung cancer: The Arg allele is preferentially retained in tumours arising in Arg/Pro germline heterozygotes
    • Papadakis ED, Soulitzis N, Spandidos DA. 2002. Association of p53 codon 72 polymorphism with advanced lung cancer: the Arg allele is preferentially retained in tumours arising in Arg/Pro germline heterozygotes. Br J Cancer 87:1013-1018.
    • (2002) Br J Cancer , vol.87 , pp. 1013-1018
    • Papadakis, E.D.1    Soulitzis, N.2    Spandidos, D.A.3
  • 131
    • 0035110767 scopus 로고    scopus 로고
    • The co-expression of p53 protein and P-glycoprotein is correlated to a poor prognosis in osteosarcoma
    • Park YB, Kim HS, Oh JH, Lee SH. 2001. The co-expression of p53 protein and P-glycoprotein is correlated to a poor prognosis in osteosarcoma. Int Orthop 24:307-310.
    • (2001) Int Orthop , vol.24 , pp. 307-310
    • Park, Y.B.1    Kim, H.S.2    Oh, J.H.3    Lee, S.H.4
  • 134
    • 3042552397 scopus 로고    scopus 로고
    • Ribozyme-mediated down-regulation of survivin expression sensitizes human melanoma cells to topotecan in vitro and in vivo
    • Feb 4 [Epub ahead of print]
    • Pennati M, Binda M, De Cesare M, Pratesi G, Folini M, Citti L, Daidone MG, Zimino F, Zaffaroni N. 2004. Ribozyme-mediated down-regulation of survivin expression sensitizes human melanoma cells to topotecan in vitro and in vivo. Carcinogenesis Feb 4 [Epub ahead of print].
    • (2004) Carcinogenesis
    • Pennati, M.1    Binda, M.2    De Cesare, M.3    Pratesi, G.4    Folini, M.5    Citti, L.6    Daidone, M.G.7    Zimino, F.8    Zaffaroni, N.9
  • 135
    • 0031873441 scopus 로고    scopus 로고
    • Characterisation of the p53 status, BCL-2 expression and radiation and platinum drug sensitivity of a panel of human ovarian cancer cell lines
    • 8
    • Pestell KE, Medlow CJ, Titley JC, Kelland LR, Walton MI. 1998. Characterisation of the p53 status, BCL-2 expression and radiation and platinum drug sensitivity of a panel of human ovarian cancer cell lines. Int J Cancer 77:913-91.8.
    • (1998) Int J Cancer , vol.77 , pp. 913-991
    • Pestell, K.E.1    Medlow, C.J.2    Titley, J.C.3    Kelland, L.R.4    Walton, M.I.5
  • 137
    • 0033851133 scopus 로고    scopus 로고
    • Does p53 status influence tumor response to anticancer therapies?
    • Pirollo KF, Bouker KB, Chang EH. 2001. Does p53 status influence tumor response to anticancer therapies? Anticancer Drugs 11:419-432.
    • (2001) Anticancer Drugs , vol.11 , pp. 419-432
    • Pirollo, K.F.1    Bouker, K.B.2    Chang, E.H.3
  • 138
    • 0037445965 scopus 로고    scopus 로고
    • Molecular targeting and pharmacogenomics in the management of advanced bladder cancer
    • Raghavan D. 2003. Molecular targeting and pharmacogenomics in the management of advanced bladder cancer. Cancer 97:2083-2089.
    • (2003) Cancer , vol.97 , pp. 2083-2089
    • Raghavan, D.1
  • 141
  • 142
    • 0033158714 scopus 로고    scopus 로고
    • Analysis of Bcl-2, Bax and Survivin genes in uterine cancer
    • Saitoh Y, Yaginuma Y, Ishikawa M. 1999. Analysis of Bcl-2, Bax and Survivin genes in uterine cancer. Int J Oncol 15:137-141.
    • (1999) Int J Oncol , vol.15 , pp. 137-141
    • Saitoh, Y.1    Yaginuma, Y.2    Ishikawa, M.3
  • 146
    • 0038751860 scopus 로고    scopus 로고
    • p53 downstream targets and chemosensitivity
    • Sax JK, El-Deiry WS. 2003. p53 downstream targets and chemosensitivity. Cell Death Differ 10:413-417.
    • (2003) Cell Death Differ , vol.10 , pp. 413-417
    • Sax, J.K.1    El-Deiry, W.S.2
  • 148
    • 0031780665 scopus 로고    scopus 로고
    • Ubiquitin, E6-AP, and their role in p53 inactivation
    • Scheffner M. 1998. Ubiquitin, E6-AP, and their role in p53 inactivation. Pharmacol Ther 78:129-139.
    • (1998) Pharmacol Ther , vol.78 , pp. 129-139
    • Scheffner, M.1
  • 149
  • 151
    • 0035863302 scopus 로고    scopus 로고
    • Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: A Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy
    • Schiller JH, Adak S, Feins RH, Keller SM, Fry WA, Livingston RB, Hammond ME, Wolf B, Sabatini L, Jett J, Kohman L, Johnson DH. 2001. Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy. J Clin Oncol 19:448-457.
    • (2001) J Clin Oncol , vol.19 , pp. 448-457
    • Schiller, J.H.1    Adak, S.2    Feins, R.H.3    Keller, S.M.4    Fry, W.A.5    Livingston, R.B.6    Hammond, M.E.7    Wolf, B.8    Sabatini, L.9    Jett, J.10    Kohman, L.11    Johnson, D.H.12
  • 153
    • 0034480069 scopus 로고    scopus 로고
    • Modulation of molecular marker expression by induction chemotherapy in locally advanced breast cancer: Correlation with the response to therapy and the expression of MDR1 and LRP
    • Schneider J, Lucas R, Sanchez J, Ruibal A, Tejerina A, Martin M. 2000a. Modulation of molecular marker expression by induction chemotherapy in locally advanced breast cancer: correlation with the response to therapy and the expression of MDR1 and LRP. Anticancer Res 20:4373-4377.
    • (2000) Anticancer Res , vol.20 , pp. 4373-4377
    • Schneider, J.1    Lucas, R.2    Sanchez, J.3    Ruibal, A.4    Tejerina, A.5    Martin, M.6
  • 156
    • 0035487104 scopus 로고    scopus 로고
    • The INK4a/ARF network in tumour suppression
    • Sherr CJ. 2001. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2:731-737.
    • (2001) Nat Rev Mol Cell Biol , vol.2 , pp. 731-737
    • Sherr, C.J.1
  • 158
  • 159
    • 0034100053 scopus 로고    scopus 로고
    • p53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients
    • Skaug V, Ryberg D, Kure EH, Arab MO, Stangeland L, Myking AO, Haugen A. 2000. p53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients. Clin Cancer Res 6:1031-1037.
    • (2000) Clin Cancer Res , vol.6 , pp. 1031-1037
    • Skaug, V.1    Ryberg, D.2    Kure, E.H.3    Arab, M.O.4    Stangeland, L.5    Myking, A.O.6    Haugen, A.7
  • 160
    • 0034168495 scopus 로고    scopus 로고
    • Tumor suppressor p53: Regulation and function
    • Somasundaram K, El-Deiry WS. 2000. Tumor suppressor p53: regulation and function. Frontier Biosci 5:424-437.
    • (2000) Frontier Biosci , vol.5 , pp. 424-437
    • Somasundaram, K.1    El-Deiry, W.S.2
  • 161
    • 0033931447 scopus 로고    scopus 로고
    • The p53 tumor suppressor gene: From molecular biology to clinical investigation
    • Soussi T. 2000. The p53 tumor suppressor gene: from molecular biology to clinical investigation. Ann N Y Acad Sci 910:121-137.
    • (2000) Ann N Y Acad Sci , vol.910 , pp. 121-137
    • Soussi, T.1
  • 162
    • 0035751937 scopus 로고    scopus 로고
    • Assessing TP53 status in human tumours to evaluate clinical outcome
    • Soussi T, Beroud C. 2001. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 1:233-240.
    • (2001) Nat Rev Cancer , vol.1 , pp. 233-240
    • Soussi, T.1    Beroud, C.2
  • 164
    • 0029587415 scopus 로고
    • The region 3′ to the major transcriptional start site of the MDR1 downstream promoter mediates activation by a subset of mutant P53 proteins
    • Strauss BE, Haas M. 1995a. The region 3′ to the major transcriptional start site of the MDR1 downstream promoter mediates activation by a subset of mutant P53 proteins. Biochem Biophys Res Commun 217:333-340.
    • (1995) Biochem Biophys Res Commun , vol.217 , pp. 333-340
    • Strauss, B.E.1    Haas, M.2
  • 165
    • 0029619819 scopus 로고
    • The MDR1 downstream promoter contains sequence-specific binding sites for wild-type p53
    • Strauss BE, Shivakumar C, Deb SP, Deb S, Haas M. 1995b. The MDR1 downstream promoter contains sequence-specific binding sites for wild-type p53. Biochem Biophys Res Commun 217:825-831.
    • (1995) Biochem Biophys Res Commun , vol.217 , pp. 825-831
    • Strauss, B.E.1    Shivakumar, C.2    Deb, S.P.3    Deb, S.4    Haas, M.5
  • 166
    • 0033953099 scopus 로고    scopus 로고
    • UCN-01 selectively enhances mitomycin C cytotoxicity in p53 defective cells which is mediated through S and/or G(2) checkpoint abrogation
    • Sugiyama K, Shimizu M, Akiyama T, Tamaoki T, Yamaguchi K, Takahashi R, Eastman A, Akinaga S. 2000. UCN-01 selectively enhances mitomycin C cytotoxicity in p53 defective cells which is mediated through S and/or G(2) checkpoint abrogation. Int J Cancer 85:703-709.
    • (2000) Int J Cancer , vol.85 , pp. 703-709
    • Sugiyama, K.1    Shimizu, M.2    Akiyama, T.3    Tamaoki, T.4    Yamaguchi, K.5    Takahashi, R.6    Eastman, A.7    Akinaga, S.8
  • 169
    • 0034063577 scopus 로고    scopus 로고
    • Regulation of expression of the multidrug resistance protein MRP1 by p53 in human prostate cancer cells
    • Sullivan GF, Yang JM, Vassil A, Yang J, Bash-Babula J, Hait WN. 2000. Regulation of expression of the multidrug resistance protein MRP1 by p53 in human prostate cancer cells. J Clin Invest 105:1261-1267.
    • (2000) J Clin Invest , vol.105 , pp. 1261-1267
    • Sullivan, G.F.1    Yang, J.M.2    Vassil, A.3    Yang, J.4    Bash-Babula, J.5    Hait, W.N.6
  • 172
    • 0036490983 scopus 로고    scopus 로고
    • BRCA1 transcriptionally regulates damaged DNA binding protein (DDB2) in the DNA repair response following UV-irradiation
    • Takimoto R, MacLachlan TK, Dicker DT, Niitsu Y, Mori T, el-Deiry WS. 2002. BRCA1 transcriptionally regulates damaged DNA binding protein (DDB2) in the DNA repair response following UV-irradiation. Cancer Biol Ther 1:177-186.
    • (2002) Cancer Biol Ther , vol.1 , pp. 177-186
    • Takimoto, R.1    MacLachlan, T.K.2    Dicker, D.T.3    Niitsu, Y.4    Mori, T.5    El-Deiry, W.S.6
  • 173
    • 0033980409 scopus 로고    scopus 로고
    • Expression of survivin and its relationship to loss of apoptosis in breast carcinomas
    • Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Tanigawa N. 2000. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 6:127-134.
    • (2000) Clin Cancer Res , vol.6 , pp. 127-134
    • Tanaka, K.1    Iwamoto, S.2    Gon, G.3    Nohara, T.4    Iwamoto, M.5    Tanigawa, N.6
  • 174
    • 0037031210 scopus 로고    scopus 로고
    • Xeroderma pigmentosum complementation group E and UV-damaged DNA-binding protein
    • Tang J, Chu G. 2002. Xeroderma pigmentosum complementation group E and UV-damaged DNA-binding protein. DNA Repair (Amst) 1:601-616.
    • (2002) DNA Repair (Amst) , vol.1 , pp. 601-616
    • Tang, J.1    Chu, G.2
  • 175
    • 0036118391 scopus 로고    scopus 로고
    • Radiation-induced phosphorylation of Chk1 at S345 is associated with p53-dependent cell cycle arrest pathways
    • Tian H, Faje AT, Lee SL, Jorgensen TJ. 2002. Radiation-induced phosphorylation of Chk1 at S345 is associated with p53-dependent cell cycle arrest pathways. Neoplasia 4:171-180.
    • (2002) Neoplasia , vol.4 , pp. 171-180
    • Tian, H.1    Faje, A.T.2    Lee, S.L.3    Jorgensen, T.J.4
  • 179
    • 0028215974 scopus 로고
    • Slow repair of pyrimidine dimers at p53 mutation hotspots in skin cancer
    • Tornaletti S, Pfeifer GP. 1994. Slow repair of pyrimidine dimers at p53 mutation hotspots in skin cancer. Science 263:1436-1438.
    • (1994) Science , vol.263 , pp. 1436-1438
    • Tornaletti, S.1    Pfeifer, G.P.2
  • 180
    • 0037325522 scopus 로고    scopus 로고
    • Modulation of multidrug resistance-associated protein 1 (MRF1) by p53 mutant in Saos-2 cells
    • Tsang WP, Chan SF, Fung KP, Kong SK, Kwok TT. 2003. Modulation of multidrug resistance-associated protein 1 (MRF1) by p53 mutant in Saos-2 cells. Cancer Chemother Pharmacol 51:161-106.
    • (2003) Cancer Chemother Pharmacol , vol.51 , pp. 161-106
    • Tsang, W.P.1    Chan, S.F.2    Fung, K.P.3    Kong, S.K.4    Kwok, T.T.5
  • 186
  • 190
    • 0035195557 scopus 로고    scopus 로고
    • The evolution of diverse biological responses to DNA damage: Insights from yeast and p53
    • Wahl GM, Carr AM. 2001. The evolution of diverse biological responses to DNA damage: insights from yeast and p53. Nat Cell Biol 3:E277-286.
    • (2001) Nat Cell Biol , vol.3
    • Wahl, G.M.1    Carr, A.M.2
  • 191
    • 0345735895 scopus 로고    scopus 로고
    • The farnesyl protein transferase inhibitor lonafarnib (SCH66336) is an inhibitor of multidrug resistance proteins 1 and 2
    • Wang EJ, Johnson WW. 2003a. The farnesyl protein transferase inhibitor lonafarnib (SCH66336) is an inhibitor of multidrug resistance proteins 1 and 2. Chemotherapy 49:303-308.
    • (2003) Chemotherapy , vol.49 , pp. 303-308
    • Wang, E.J.1    Johnson, W.W.2
  • 192
    • 1342332342 scopus 로고    scopus 로고
    • Chemosensitization and radiosensitization of human cancer by antisense anti-MDM2 oligonucleotides: In vitro and in vivo activities and mechanisms
    • Wang H, Oliver P, Zhang Z, Agrawal S, Zhang R. 2003b. Chemosensitization and radiosensitization of human cancer by antisense anti-MDM2 oligonucleotides: In vitro and in vivo activities and mechanisms. Ann N Y Acad Sci 1002:217-235.
    • (2003) Ann N Y Acad Sci , vol.1002 , pp. 217-235
    • Wang, H.1    Oliver, P.2    Zhang, Z.3    Agrawal, S.4    Zhang, R.5
  • 194
    • 0032535308 scopus 로고    scopus 로고
    • Transcriptional suppression of multidrug resistance-associated protein (MRP) gene expression by wild-type p53
    • Wang Q, Beck WT. 1998. Transcriptional suppression of multidrug resistance-associated protein (MRP) gene expression by wild-type p53. Cancer Res 58:5762-5769.
    • (1998) Cancer Res , vol.58 , pp. 5762-5769
    • Wang, Q.1    Beck, W.T.2
  • 198
    • 0030754662 scopus 로고    scopus 로고
    • Polymorphisms of H-ras-1 and p53 in breast cancer and lung cancer: A meta-analysis
    • Weston A, Godbold JH. 1997. Polymorphisms of H-ras-1 and p53 in breast cancer and lung cancer: a meta-analysis. Environ Health Perspect 105:919-926.
    • (1997) Environ Health Perspect , vol.105 , pp. 919-926
    • Weston, A.1    Godbold, J.H.2
  • 199
    • 0036300312 scopus 로고    scopus 로고
    • 7-Hydroxystaurosporine (UCN-01) preferentially sensitizes cells with a disrupted TP53 to gamma radiation in lung cancer cell lines
    • Xiao HH, Makeyev Y, Butler J, Vikrani B, Franklin WA. 2002. 7-Hydroxystaurosporine (UCN-01) preferentially sensitizes cells with a disrupted TP53 to gamma radiation in lung cancer cell lines. Radiat Res 158:84-93.
    • (2002) Radiat Res , vol.158 , pp. 84-93
    • Xiao, H.H.1    Makeyev, Y.2    Butler, J.3    Vikrani, B.4    Franklin, W.A.5
  • 201
    • 85010788247 scopus 로고    scopus 로고
    • Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer
    • Yamashita H, Nishio M, Toyama T, Sugiura H, Zhang Z, Kobayashi S, Iwase H. 2004. Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer. Breast Cancer Res 6:R24-30.
    • (2004) Breast Cancer Res , vol.6
    • Yamashita, H.1    Nishio, M.2    Toyama, T.3    Sugiura, H.4    Zhang, Z.5    Kobayashi, S.6    Iwase, H.7
  • 202
    • 0029962567 scopus 로고    scopus 로고
    • Wild-type p53 protein potentiates cytotoxicity of therapeutic agents in human colon cancer cells
    • Yang B, Eshleman JR, Berger NA, Markowitz SD. 1996. Wild-type p53 protein potentiates cytotoxicity of therapeutic agents in human colon cancer cells. Clin Cancer Res 2:1649-1657.
    • (1996) Clin Cancer Res , vol.2 , pp. 1649-1657
    • Yang, B.1    Eshleman, J.R.2    Berger, N.A.3    Markowitz, S.D.4
  • 204
    • 0037108873 scopus 로고    scopus 로고
    • UCN-01 inhibits p53 up-regulation and abrogates gamma-radiation-induced G(2)-M checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1
    • Yu Q, La Rose J, Zhang H, Takemura H, Kolm KW, Pommier Y. 2002. UCN-01 inhibits p53 up-regulation and abrogates gamma-radiation-induced G(2)-M checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1. Cancer Res 62:5743-5748.
    • (2002) Cancer Res , vol.62 , pp. 5743-5748
    • Yu, Q.1    La Rose, J.2    Zhang, H.3    Takemura, H.4    Kolm, K.W.5    Pommier, Y.6
  • 206
    • 0032568221 scopus 로고    scopus 로고
    • The role of MAP4 expression in the sensitivity to paclitaxel and resistance to vinca alkaloids in p53 mutant cells
    • Zhang CC, Yang JM, White E, Murphy M, Levine A, Hait WN. 1998. The role of MAP4 expression in the sensitivity to paclitaxel and resistance to vinca alkaloids in p53 mutant cells. Oncogene 16:1617-1624.
    • (1998) Oncogene , vol.16 , pp. 1617-1624
    • Zhang, C.C.1    Yang, J.M.2    White, E.3    Murphy, M.4    Levine, A.5    Hait, W.N.6
  • 207
    • 0033178994 scopus 로고    scopus 로고
    • DNA damage increases sensitivity to vinca alkaloids and decreases sensitivity to taxanes through p53-dependent repression of microtubule- associated protein 4
    • Zhang CC, Yang JM, Bash-Babula J, White E, Murphy M, Levine AJ, Hait WN. 1999. DNA damage increases sensitivity to vinca alkaloids and decreases sensitivity to taxanes through p53-dependent repression of microtubule- associated protein 4. Cancer Res 59:3663-3670.
    • (1999) Cancer Res , vol.59 , pp. 3663-3670
    • Zhang, C.C.1    Yang, J.M.2    Bash-Babula, J.3    White, E.4    Murphy, M.5    Levine, A.J.6    Hait, W.N.7
  • 208
  • 209
    • 0037942897 scopus 로고    scopus 로고
    • Antisense oligonucleotide inhibitors of MDM2 oncogene expression
    • Zhang R, Wang H. 2003b. Antisense oligonucleotide inhibitors of MDM2 oncogene expression. Methods Mol Med 85:205-222.
    • (2003) Methods Mol Med , vol.85 , pp. 205-222
    • Zhang, R.1    Wang, H.2
  • 210
    • 1642377946 scopus 로고    scopus 로고
    • Radiosensitization by antisense anti-MDM2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer models
    • Zhang Z, Wang H, Prasad G, Li M, Yu D, Bonner JA, Agrawal S, Zhang R. 2004. Radiosensitization by antisense anti-MDM2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer models. Clin Cancer Res 10:1263-1273.
    • (2004) Clin Cancer Res , vol.10 , pp. 1263-1273
    • Zhang, Z.1    Wang, H.2    Prasad, G.3    Li, M.4    Yu, D.5    Bonner, J.A.6    Agrawal, S.7    Zhang, R.8
  • 211
    • 0141919562 scopus 로고    scopus 로고
    • PTEN reverses MDM2-mediated chemotherapy resistance by interacting with p53 in acute lymphoblastic leukemia cells
    • Zhou M, Gu L, Findley HW, Jiang R, Woods WG. 2003. PTEN reverses MDM2-mediated chemotherapy resistance by interacting with p53 in acute lymphoblastic leukemia cells. Cancer Res 63:6357-6362.
    • (2003) Cancer Res , vol.63 , pp. 6357-6362
    • Zhou, M.1    Gu, L.2    Findley, H.W.3    Jiang, R.4    Woods, W.G.5
  • 212
    • 1842789760 scopus 로고    scopus 로고
    • Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: A systematic analysis of primary and metastatic tumor tissue
    • Zigeuner R, Ratschek M, Rehak P, Schips L, Langner C. 2004. Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue. Urology 63:651-655.
    • (2004) Urology , vol.63 , pp. 651-655
    • Zigeuner, R.1    Ratschek, M.2    Rehak, P.3    Schips, L.4    Langner, C.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.